Investigating Amgen's Standing In Biotechnology Industry Compared To Competitors
Portfolio Pulse from Benzinga Insights
Amgen (NASDAQ:AMGN) is evaluated against its biotech industry competitors, showing a lower P/E ratio, suggesting undervaluation, but higher P/B and P/S ratios, indicating potential overvaluation based on book value and sales. Amgen's ROE, EBITDA, gross profit, and revenue growth are strong compared to the industry, but a high debt-to-equity ratio presents financial risk. Key competitors include AbbVie, Vertex Pharmaceuticals, Gilead Sciences, Regeneron Pharmaceuticals, Biogen, BioNTech, Genmab, Biomarin Pharmaceutical, Incyte, Neurocrine Biosciences, United Therapeutics, Exelixis, and Grifols.
November 10, 2023 | 4:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Amgen's lower P/E ratio suggests undervaluation, while higher P/B and P/S ratios may indicate overvaluation. Strong ROE, EBITDA, gross profit, and revenue growth are positives, but a high debt-to-equity ratio introduces financial risk.
The mixed financial indicators suggest a neutral short-term impact. The undervaluation based on P/E could attract investors, but the overvaluation based on P/B and P/S, along with high debt levels, could deter them. Strong profitability metrics are positive, but the high debt-to-equity ratio may concern investors about financial stability.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100